The purpose of the meeting was to reach final agreement on the design of the Phase 3 pivotal clinical trial for PBI-4050 in patients with idiopathic pulmonary fibrosis (IPF).
Based on recommendations from the FDA, enrollment criteria will be greatly simplified such that the study will enroll patients with mild-to-moderate IPF, regardless of whether they are on background standard of care with nintedanib (OFEV) or not. Patients taking pirfenidone will be excluded because of a known drug-drug interaction between pirfenidone and PBI-4050.
The study will provide efficacy data on both PBI-4050 as a stand-alone agent, and as an add-on to nintedanib, and will be part of the dataset to support a simple, all-inclusive indication "for the treatment of IPF."
The primary endpoint is the annual rate of decline in forced vital capacity (FVC).
PBI-4050 has excellent safety and efficacy profiles in a large number of animal models of fibrosis affecting different organs, including the lung, liver, heart, kidney, and pancreas. The effects of PBI-4050 demonstrated in animal models have been replicated in Phase 2 studies in IPF, in Type 2 diabetes with metabolic syndrome, and in Alström syndrome.
Prometic develops bioseparations, plasma-derived therapeutics and small-molecule therapeutic products targeting unmet medical needs in the fields of fibrosis, cancer, and autoimmune diseases/inflammation.The company also offers technologies for large-scale purification of biologics, drug development, proteomics, and the elimination of pathogens to a growing base of industry leaders.
Headquartered in Laval,Canada, the company has R and D facilities in the UK, the US, and Canada; manufacturing facilities in the UK; and commercial activities in the US, Canada, Europe, and Asia.
FDA approves Dupixent as first targeted therapy for rare skin disease bullous pemphigoid
Hoth Therapeutics regains Nasdaq compliance
TME Pharma and SERI partner to advance NOX-E36 in ophthalmology through option framework agreement
Merry Life launches TML-6 global Phase II trial for Alzheimer's Disease
Galderma's nemolizumab recommended for NHS funding in England and Wales for atopic dermatitis
UCB announces BIMZELX (bimekizumab-bkzx) three-year data at EULAR 2025
Vivoryon Therapeutics presents positive meta-analysis data for varoglutamstat
Sanofi's rilzabrutinib granted US orphan drug designation for sickle cell disease
Sanofi to acquire Blueprint Medicines in USD9.5bn rare disease deal
Genentech reports sustained two-year benefits from fenebrutinib in relapsing multiple sclerosis
RemeGen secures approval in China for Telitacicept in treating generalised myasthenia gravis
TME Pharma announces extension of financial visibility to May 2026